Foxtail millet (kangni) and sorghum (jowar) are the most clinically validated millets for type 2 diabetes management. Foxtail millet, with a GI of approximately 50, is particularly effective due to its high resistant starch content and slow-digesting protein matrix that attenuates postprandial glucose spikes. A landmark meta-analysis published in Frontiers in Nutrition (2021) by Anitha et al., analyzing 80 clinical trials across 19 countries, found that millet consumption reduced postmeal blood glucose by an average of 27% and fasting blood glucose by 12% compared to refined grain control diets. Pearl millet additionally improves insulin receptor sensitivity through its magnesium and polyphenol content, making it valuable for insulin-resistant type 2 diabetics.
Key Points
Foxtail millet (GI ~50): resistant starch and slow protein digestion reduce postmeal glucose spikes by up to 27%
Sorghum (GI 45–50): kafirin protein creates a starch barrier that slows glucose absorption — one of the lowest GI cereals
Pearl millet improves insulin receptor sensitivity via magnesium-dependent GLUT4 transporter upregulation in muscle cells
Finger millet tannins inhibit α-glucosidase and α-amylase enzymes, reducing starch hydrolysis to glucose in the gut
Any millet replacing refined rice or wheat in the diet reduces daily glycemic load significantly, improving long-term HbA1c
Evidence Base
The most comprehensive evidence base — Anitha et al., Frontiers in Nutrition (2021) — covering 80 controlled trials confirms that regular millet consumption is one of the most effective dietary strategies for type 2 diabetes prevention and glycemic management.
© 2023 - 2026 Millets News. All rights reserved.